Table 3 HBV-ACLFs and HBV-ADs comparing with c-index of CLIF-C ACLFs and CLIF-C ADs and with MELDs andMELD-Nas.
C-index | ||||||||
|---|---|---|---|---|---|---|---|---|
28 days | P | 90 days | P | 180 days | P | 360 days | p | |
Patients with ACLF in the whole study | ||||||||
HBV-ACLFs | 0.654 (0.604–0.705) | 0.645 (0.596–0.694) | 0.644 (0.595–0.693) | 0.640 (0.591–0.688) | ||||
CLIF-C ACLFs | 0.704 (0.661–0.748) | 0.023 | 0.685 (0.643–0.727) | 0.057 | 0.687 (0.645–0.728) | 0.041 | 0.682 (0.640–0.723) | 0.046 |
MELDs | 0.554 (0.497–0.610) | <0.001 | 0.543 (0.490–0.596) | <0.001 | 0.543 (0.491–0.595) | <0.001 | 0.540 (0.488–0.591) | <0.001 |
MELD-Nas | 0.549 (0.493–0.605) | <0.001 | 0.541 (0.488–0.594) | <0.001 | 0.541 (0.488–0.594) | <0.001 | 0.537 (0.486–0.589) | <0.001 |
Patients without ACLF in the whole study | ||||||||
HBV-ADs | 0.737 (0.659–0.814) | 0.716 (0.650–0.781) | 0.720 (0.659–0.782) | 0.721 (0.666–0.775) | ||||
CLIF-C ADs | 0.733 (0.662–0.803) | 0.92 | 0.724 (0.663–0.784) | 0.796 | 0.728 (0.671–0.784) | 0.783 | 0.728 (0.677–0.779) | 0.788 |
MELDs | 0.667 (0.575–0.759) | 0.08 | 0.653 (0.580–0.725) | 0.056 | 0.657 (0.589–0.724) | 0.042 | 0.639 (0.577–0.700) | 0.003 |
MELD-Nas | 0.719 (0.643–0.796) | 0.653 | 0.710 (0.646–0.773) | 0.886 | 0.701 (0.640–0.762) | 0.54 | 0.682 (0.626–0.738) | 0.164 |
